Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | ABCB1 | P08183 | 8/20 | 0.59 |
| ▸ | HTR7 | P34969 | 1/20 | 0.58 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3440576 | 1.00 | MAPT (0.67) | MAPTMAPK1L3MBTL1ABCB1HTR7 | |
| SCHEMBL3440503 | 0.91 | MAPK1 (0.71) | MAPTMAPK1L3MBTL1ABCB1HTR7 | |
| SCHEMBL3440502 | 0.91 | MAPK1 (0.71) | MAPTMAPK1L3MBTL1ABCB1HTR7 | |
| SCHEMBL31233271 | 0.88 | HTR7 (0.67) | MAPTMAPK1L3MBTL1ABCB1HTR7 | |
| SCHEMBL25198533 | 0.87 | MAPT (0.62) | MAPTMAPK1L3MBTL1ABCB1HTR7 | |
| SCHEMBL30383719 | 0.87 | MAPT (0.62) | MAPTMAPK1L3MBTL1ABCB1HTR7 | |
| SCHEMBL25192668 | 0.84 | HTR7 (0.70) | MAPTMAPK1L3MBTL1ABCB1HTR7 | |
| SCHEMBL25192218 | 0.84 | HTR7 (0.70) | MAPTMAPK1L3MBTL1ABCB1HTR7 | |
| SCHEMBL30384498 | 0.84 | HTR7 (0.62) | MAPTMAPK1L3MBTL1ABCB1HTR7 | |
| SCHEMBL3440769 | 0.84 | HTR7 (0.62) | MAPTMAPK1L3MBTL1ABCB1HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807712-B2 | Oxy substituted chalcones as antihyperglycemic and antidyslipidemic agents | PRATAP RAM | 2010-10-05 | — | — | US | claimed |
| US-20060142303-A1 | Oxy substituted chalcones as antihyperglycemic and antidyslipidemic agents | PRATAP RAM | 2006-06-29 | — | — | US | claimed |
| US-7807712-B2 | Oxy substituted chalcones as antihyperglycemic and antidyslipidemic agents | PRATAP RAM | 2010-10-05 | — | — | US | disclosed |
| US-20060142303-A1 | Oxy substituted chalcones as antihyperglycemic and antidyslipidemic agents | PRATAP RAM | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142303-A1 | Oxy substituted chalcones as antihyperglycemic and antidyslipidemic agents | LIPC, CYP46A1, HMGCR | MAPT 4801/4885MAPK1 1830/4885L3MBTL1 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.